Refractory chronic cough represents a significant unmet need with no FDA-approved treatment options and $11B total addressable global marketFirst-in-human Phase 1/1b single/multiple dose study in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback